Cyclodextrin derivatives conjugated with aromatic moieties as pH-responsive drug carriers for anthracycline

Journal of Physical Chemistry B

Volumn 117, Issue 43, 2013, Pages 13444-13450

  Swiech, Olga ^a   Dutkiewicz, Paula ^a   Wójciuk, Karolina ^b   Chmurski, Kazimierz ^a   Kruszewski, Marcin ^b,c   Bilewicz, Renata ^a  

^a UNIVERSITY OF WARSAW   (Poland)

^b INSTITUTE OF NUCLEAR CHEMISTRY AND TECHNOLOGY   (Poland)

^c INSTITUTE OF AGRICULTURAL MEDICINE   (Poland)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICANCER DRUG; AROMATIC MOIETIES; CERVICAL CANCER CELLS; COMPLEX COMPONENTS; COMPLEX FORMATION CONSTANTS; CYCLODEXTRIN DERIVATIVES; FORMATION CONSTANTS; ORDERS OF MAGNITUDE;

AROMATIZATION; CELL CULTURE; DRUG DELIVERY; NITROGEN COMPOUNDS; SYNTHESIS (CHEMICAL);

AROMATIC COMPOUNDS;

ANTHRACYCLINE; ANTINEOPLASTIC ANTIBIOTIC; CYCLODEXTRIN; DOXORUBICIN; DRUG CARRIER;

ARTICLE; CELL PROLIFERATION; CHEMICAL STRUCTURE; CHEMISTRY; DOSE RESPONSE; DRUG EFFECT; DRUG SCREENING; HELA CELL LINE; HUMAN; PH; STRUCTURE ACTIVITY RELATION; TUMOR CELL LINE;

ANTHRACYCLINES; ANTIBIOTICS, ANTINEOPLASTIC; CELL LINE, TUMOR; CELL PROLIFERATION; CYCLODEXTRINS; DOSE-RESPONSE RELATIONSHIP, DRUG; DOXORUBICIN; DRUG CARRIERS; DRUG SCREENING ASSAYS, ANTITUMOR; HELA CELLS; HUMANS; HYDROGEN-ION CONCENTRATION; MODELS, MOLECULAR; MOLECULAR STRUCTURE; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 84887117841     PISSN: 15206106     EISSN: 15205207     Source Type: Journal    
DOI: 10.1021/jp4060632     Document Type: Article

References (32)

1. Chaires, J. B.; Herrera, J. E.; Waring, M. J. Preferential Binding of Daunomycin to 5′ATCG and 5′ATGC Sequences Revealed by Footprinting Titration Experiments Biochemistry 1990, 29, 6145-6153
2. Steinherz, L. J.; Steinherz, P. G.; Tan, C. T.; Heller, G.; Murphy, M. L. Cardiac Toxicity 4 to 20 years after Completing Anthracycline Therapy JAMA, J. Am. Med. Assoc. 1991, 266, 1672-1677
3. Tinkov, S.; Winter, G.; Coester, C.; Bekeredjian, R. New Doxorubicin-loaded Phospholipid Microbubbles for Targeted Tumor Therapy: Part I-Formulation Development and in-vitro Characterization J. Controlled Release 2010, 143, 143-150
4. Šimùnek, T.; Štìrba, M.; Popelová, O.; Adamcová, M.; Hrdina, R.; Geršl, V. Anthracycline-induced Cardiotoxicity: Overview of Studies Examining the Roles of Oxidative Stress and Free Cellular Iron Pharmacol. Rep. 2009, 61, 154-171
5. 3+ by Anthracyclines. 1. The Importance of Pendant Hydroxyl Functionality J. Phys. Chem. B 2013, 117, 6859-6867
6. 3+ by Anthracyclines. 2. The Roles of Methoxy and Daunosamine Functionalities J. Phys. Chem. B 2013, 117, 6868-6873
7. Nawara, K.; Krysinski, P.; Blanchard, G. J. Photoinduced Reactivity of Doxorubicin: Catalysis and Degradation J. Phys. Chem. A 2012, 116, 4330-4337
8. 2 RSC Adv. 2012, 2, 4059-4061
9. Husain, N.; Ndou, T. T.; Munoz De La Pena, A.; Warner, I. M. Complexation of Doxorubicin with β- and γ-Cyclodextrins Appl. Spectrosc. 1992, 46, 652-658
10. Brewster, M. E.; Loftsson, T.; Estes, K. S.; Lin, J. L.; Fridriksdottir, H.; Bodor, N. Effects of Various Cyclodextrins on Solution Stability and Dissolution Rate of Doxorubicin Hydrochloride Int. J. Pharm. 1992, 79, 289-299
11. Schneider, Y. J.; Baurain, R.; Zenebergh, A.; Trouet, A. DNA-Binding Parameters of Daunorubicin and Doxorubicin in the Conditions Used for Studying the Interaction of Anthracycline-DNA Complexes with Cells in Vitro Cancer Chemother. Pharmacol. 1979, 2, 7-10
12. Yamanoi, T.; Yoshida, N.; Oda, Y.; Akaike, E.; Tsutsumida, M.; Kobayashi, N.; Osumi, K.; Yamamoto, K.; Fujita, K.; Takahashi, K.; Hattori, K. Synthesis of mono -Glucose-Branched Cyclodextrins with a High Inclusion Ability for Doxorubicin and Their Efficient Glycosylation Using Mucor hiemalis endo -β- N -Acetylglucosaminidase Bioorg. Med. Chem. Lett. 2005, 15, 1009-1013
13. Oda, Y.; Kobayashi, N.; Yamanoi, T.; Katsuraya, K.; Takahashi, K.; Hattori, K. β-Cyclodextrin Conjugates with Glucose Moieties Designed as Drug Carriers: Their Syntheses, Evaluations Using Concanavalin A and Doxorubicin, and Structural Analyses by NMR Spectroscopy Med. Chem. 2008, 4, 244-255
14. Kralova, J.; Kejik, Z.; Briza, T.; Pouckova, P.; Kral, A.; Martasek, P.; Kral, V. Porphyrin-Cyclodextrin Conjugates as a Nanosystem for Versatile Drug Delivery and Multimodal Cancer Therapy J. Med. Chem. 2010, 53, 128-138
15. Swiech, O.; Mieczkowska, A.; Chmurski, K.; Bilewicz, R. Intermolecular Interactions between Doxorubicin and β-Cyclodextrin 4-Methoxyphenol Conjugates J. Phys. Chem. B 2012, 116, 1765-1771
16. Martin, F. Clinical Pharmacology and Antitumor Efficacy of DOXIL (Pegylated Liposomal Doxorubicin). In Medical Applications of Liposomes; Lasic, D. D.; Papahadjopoulos, D., Eds.; Elsevier: New York, 1998; pp 635-688.
17. Hrubý, M.; Koňak, Č.; Ulbrich, K. Polymeric Micellar pH-Sensitive Drug Delivery System for Doxorubicin J. Controlled Release 2005, 103, 137-148
18. Li, L.; Zhao, M.; Li, W.; Wang, Y.; Zhang, Z.; An, R.; Peng, S. Self-Complexation and Complexation-Controlled Target Cancer Therapy Med. Chem. Commun. 2012, 3, 1059-1061
19. Irie, T.; Uekama, K. Pharmaceutical Applications of Cyclodextrins. III. Toxicological Issues and Safety Evaluation J. Pharm. Sci. 1997, 86, 147-162
20. Uekama, K.; Hirayama, F.; Irie, T. Cyclodextrin Drug Carrier Systems Chem. Rev. 1998, 98, 2045-2076
21. Krieger, E.; Darden, T.; Nabuurs, S.; Finkelstein, A.; Vriend, G. Making Optimal Use of Empirical Energy Functions: Force-Field Parameterization in Crystal Space Proteins 2004, 57, 678-683
22. Duan, Y.; Wu, C.; Chowdhury, S.; Lee, M. C.; Xiong, G.; Zhang, W.; Yang, R.; Cieplak, P.; Luo, R.; Lee, T.; Caldwell, J.; Wang, J.; Kollman, P. A Point-Charge Force Field for Molecular Mechanics Simulations of Proteins Based on Condensed-Phase Quantum Mechanical Calculations J. Comput. Chem. 2003, 24, 1999-2012
23. Essman, U.; Perera, L.; Berkowitz, M. L.; Darden, T.; Lee, H.; Pedersen, L. G. A Smooth Particle Mesh Ewald Method J. Chem. Phys. B 1995, 103, 8577-8593
24. Jakalian, A.; Jack, D. B.; Bayly, C. I. Fast, Efficient Generation of High-Quality Atomic Charges. AM1-BCC Model: II. Parameterization and Validation J. Comput. Chem. 2002, 23, 1623-1641
25. Osa, T.; Matsue, T.; Fujihira, T. Cyclodextrin-Nitrophenol Systems Studied by Polarography Heterocycles 1977, 6, 1833-1839
26. Chatijgakis, A. K.; Donze, C.; Coleman, A. W. Solubility Behavior of β-Cyclodextrin in Water/Cosolvent Mixtures Anal. Chem. 1992, 64, 1632-1634
27. Fotakis, G.; Timbrell, J. A. In Vitro Cytotoxicity Assays-Comparison of LDH, Neural Red, MTT and Protein Assay in Hepatoma Cell Lines Following Exposure to Cadmium Chloride Toxicol. Lett. 2006, 160, 171-177
28. McGaughey, G. B.; Gagne, M.; Rappe, A. K. π-Stacking Interactions: Alive and Well in Proteins J. Biol. Chem. 1998, 273, 15458-15463
29. Hunter, C. A.; Sanders, J. K. M. The Nature of π-π Interactions J. Am. Chem. Soc. 1990, 112, 5525-5534
30. Singh, A.; Misra, V.; Thimmulappa, R. K.; Lee, H.; Ames, S.; Hoque, M. O.; Herman, J. G.; Baylin, S. B.; Sidransky, D.; Gabrielson, E.; Brock, M. V.; Biswal, S. Dysfunctional KEAP1-NRF2 Interaction in Non-Small-Cell Lung Cancer PLoS Med. 2006, 3, 1865-1876
31. Kastamoulas, M.; Chondrogiannis, G.; Kanavaros, P.; Vartholomatos, G.; Bai, M.; Briasoulis, E.; Arvanitis, D.; Galani, V. Cytokine Effects on Cell Survival and Death of A549 Lung Carcinoma Cells Cytokine 2013, 61, 816-825
32. Tanaka, H.; Kominato, K.; Yamamoto, R.; Yoshioka, T.; Nishida, H.; Tone, H.; Okamoto, R. Synthesis of Doxorubicin-Cyclodextrin Conjugates J. Antibiot. 1994, 47, 1025-1029